Opaleye Management’s Protalix BioTherapeutics PLX Stock Holding History

Opaleye Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-340,000	Closed	-$738K	–	63
2026 Q1	$738K	Sell	340,000 -2,138,176	-86%	-$5.31M	0.1%	51
2025 Q4	$4.46M	Sell	2,478,176 -102,380	-4%	-$209K	0.59%	34
2025 Q3	$5.73M	Buy	+2,580,556	New	+$4.2M	0.81%	26
2019 Q3	–	Sell	-100,000	Closed	-$469K	–	55
2019 Q2	$469K	Buy	+100,000	New	+$423K	0.14%	41
2019 Q1	–	Sell	-250,000	Closed	-$777K	–	58
2018 Q4	$777K	Hold	250,000	–	–	0.29%	41
2018 Q3	$1.82M	Sell	250,000 -60,000	-19%	-$301K	0.46%	39
2018 Q2	$1.33M	Sell	310,000 -16,000	-5%	-$71.1K	0.35%	33
2018 Q1	$1.76M	Buy	326,000 +143,500	+79%	+$944K	0.5%	32
2017 Q4	$1.21M	Buy	+182,500	New	+$1.23M	0.39%	31

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Opaleye Management's PLX Position: Q2 2026 in Review

Opaleye Management sold out of Protalix BioTherapeutics (PLX) in Q2 2026, closing a stake of 340,000 shares — an estimated $738K sold.

Opaleye Management first reported a position in PLX in Q4 2017 and held it in 9 quarters. The position peaked at $5.73M in Q3 2025. 102 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Opaleye Management reported no remaining Protalix BioTherapeutics position as of Q2 2026 after selling out during the quarter.
Opaleye Management sold 340,000 Protalix BioTherapeutics shares in Q2 2026, an estimated $738K.
Opaleye Management first reported a position in Protalix BioTherapeutics in Q4 2017 and held it in 9 quarters.
Opaleye Management's Protalix BioTherapeutics position peaked at $5.73M in Q3 2025.
102 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Opaleye Management's 13F filing for Q2 2026, filed 14 Aug 2026.